Mounjaro is a medication containing the active ingredient tirzepatide [1]. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1][2]. It is developed by Eli Lilly and Company [3].
How does tirzepatide work in the body?
Tirzepatide works by activating GIP and GLP-1 receptors [1][2]. GIP and GLP-1 are hormones that play a role in regulating blood sugar [1]. By acting on these receptors, tirzepatide helps to lower blood glucose levels [1]. It also promotes weight loss [1].
What conditions is Mounjaro approved for?
Mounjaro is approved for adults with type 2 diabetes mellitus to improve glycemic control [1]. It is also indicated for chronic weight management in adults who are obese or overweight and have at least one weight-related comorbidity [1].
How does Mounjaro compare to other diabetes and weight loss medications?
As a dual GIP and GLP-1 receptor agonist, Mounjaro targets two incretin hormones that are involved in glucose metabolism and appetite regulation [1][2]. Many other medications target only GLP-1 receptors. This dual mechanism is associated with significant reductions in blood sugar and body weight in clinical studies [1].
When did Mounjaro receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Mounjaro for the treatment of type 2 diabetes in May 2022 [1]. Approval for chronic weight management was granted in November 2023 [1].
What are the potential side effects of Mounjaro?
Common side effects of Mounjaro include nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal pain [1]. More serious side effects can occur, including pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and certain types of thyroid tumors [1]. Patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Mounjaro [1].
What is the patent status for Mounjaro?
Drug patents are complex and can involve multiple patents covering the drug substance, manufacturing processes, and methods of use. Information regarding the specific patent landscape for tirzepatide and Mounjaro can be found on resources that track pharmaceutical patents [4].
Sources:
[1] https://www.mounjaro.com/
[2] https://diabetes.diabetesjournals.org/content/71/Supplement_1/1091-OR
[3] https://investor.lilly.com/news-releases/news-release-details/eli-lilly-announces-fda-approval-mounjaro-tirzepatide-injection-treatment
[4] https://drugpatentwatch.com/